Business context and reporting period
Novelos Therapeutics, Inc. filed this unaudited Form 10-Q for the quarter ended September 30, 2013. The filing describes a development-stage cancer drug company; its programs include LIGHT (imaging), HOT (radiotherapeutic), and preclinical GLOW2. The registrant named in the filing is Novelos Therapeutics, Inc., although the request identifies Cellectar Biosciences, Inc.
Financial results and liquidity
The company reported no product revenue. It continues to incur research and development costs and losses while developing its candidates.
| Metric | Q3 2013 | Q3 2012 | Nine months 2013 | Nine months 2012 |
|---|---|---|---|---|
| Research and development expense | $2.07 million | $1.25 million | $5.31 million | $3.90 million |
| General and administrative expense | $0.84 million | $0.80 million | $3.04 million | $2.70 million |
| Operating loss | ($2.91 million) | ($2.05 million) | ($8.35 million) | ($6.59 million) |
| Net loss | ($1.32 million) | ($2.05 million) | ($6.83 million) | ($6.64 million) |
| Net loss per common share | ($0.02) | ($0.06) | ($0.12) | ($0.18) |
| Cash used in operating activities | Not stated by quarter | ($6.48 million) | ($4.89 million) |
Q3 net loss was lower than the prior-year quarter mainly because of a $1.60 million non-cash gain from revaluing derivative warrants. For the nine-month comparison, a $2.26 million warrant revaluation gain partly offset higher operating costs; 2013 also included a $0.74 million non-cash loss on issuing derivative warrants. These items affect reported earnings but are not operating cash flows.
At September 30, 2013, cash and cash equivalents were $5.11 million, working capital was $0.87 million, and total assets were $9.65 million. Total liabilities were $5.22 million, including a $3.47 million derivative-warrant liability and $0.45 million in long-term notes payable; stockholders’ equity was $4.43 million. The company reported $6.48 million of operating cash outflow for the first nine months, offset in part by $5.04 million of financing cash flow, principally net proceeds of $4.98 million from its February public offering. The filing says cash was expected to fund operations through February 2014. No operating margin is meaningful because the company had no product revenue.
Material changes, outlook and risks
- Nine-month R&D expense increased 36% year over year, driven principally by GLOW2 preclinical/IND-enabling work, clinical-material manufacturing, and additional research staffing. G&A rose 13%, including higher consulting costs; the 2012 comparison included a $125,000 insurance reimbursement for legal expenses.
- The February 2013 offering raised $5.50 million gross and $4.98 million net. It included warrants with down-round provisions, classified as derivative liabilities. At September 30, 36.78 million warrants and 6.10 million options were outstanding and excluded from diluted loss per share as antidilutive.
- Management expected continuing operating losses and said additional financing would be needed to execute its plan beyond February 2014. It planned to pursue equity or debt financing, a strategic transaction, or other alternatives, but gave no assurance funds would be available on acceptable terms or in time. No revenue or profitability guidance was provided.
- Management expected LIGHT’s Phase 2 glioma trial to begin enrolling by the end of Q4 2013 and planned to submit a GLOW2 IND by the end of Q1 2014. These are forward-looking plans, not reported outcomes. HOT’s Phase 1b dose-escalation trial was ongoing.
- After quarter-end, CEO Harry Palmin left and Simon Pedder became Acting CEO; a new employment agreement, option grants, board departures and restructuring, and relocation of executive offices to Madison were disclosed. The company estimated approximately $330,000 in cash exit costs for closing the Newton office, in addition to other transition and option-related costs.
- ZAO BAM’s appeal in a dispute over legacy NOV-002 rights was docketed in November 2013. Management did not anticipate a material adverse financial effect. The filing also identifies financing availability, clinical and regulatory outcomes, manufacturing, and retention of key personnel as significant risks.
Key facts for investors to verify
- Whether the company secured financing after the stated February 2014 cash runway, and the resulting dilution or other financing terms.
- Actual cash burn and the impact of the October waiver that made approximately $1.88 million previously restricted for manufacturing construction available for operations.
- Progress and results of LIGHT, HOT, and GLOW2 trials and regulatory milestones versus the stated plans.
- Final costs and accounting effects of management changes, board option modifications, and the Newton office closure.
- Outcome and potential consequences of the ZAO BAM appeal and the valuation of derivative warrants.